13May 2022
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting

To evaluate the safety and efficacy of favipiravir, which is prescribed for treating patients with mild-to-moderate coronavirus disease 2019 (COVID-19) in India. This prospective, open-label, multicenter, single-arm postmarketing study was conducted in India. Patients with mild-to-moderate COVID-19 received favipiravir (3600 mg [1800 mg orally twice daily] on the first day, followed by 800 mg orally twice daily, up to a maximum of 14 days) as a part of their treatment. A total of 1083 patients were enrolled in this study from December 2020 to June 2021. In the real-world setting, favipiravir was well-tolerated, and no new safety signals were detected.

  • #family health

Like

Save

Share